Keir S D, Mitchell W J, Feldman L T, Martin J R
Laboratory of Experimental Neuropathology, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Neurovirol. 1995 Sep;1(3-4):259-67. doi: 10.3109/13550289509114022.
One problem in devising strategies of gene transfer to the nervous system is targeting specific neuronal populations. To evaluate the potential for using herpes simplex virus (HSV) as a vector for gene transfer to spinal cord motor neurons, the HSV-1 mutant LAT-LTR in which the E. coli beta-galactosidase gene is expressed under control of the HSV LAT core promoter (LAT) and the Moloney murine leukemia virus long terminal repeat (LTR) was inoculated unilaterally into the gastrocnemius muscle. Infectious virus was isolated from the spinal cord on days 3-7 post inoculation (PI). Immunocytochemical labeling of HSV antigen was detected in ipsilateral ventral horn neurons in the spinal cord at day 3 PI and had spread to contiguous spinal cord regions by day 6 PI. No viral antigen was detected at 14 or 28 DPI. beta-galactosidase expression (driven by the LAT-LTR promoter) was detected in neurons of the ventral horn on days 3, 6, 14, and 28 PI. Histological analysis showed mild lesions in the ventral horn on day 3 PI which progressed through days 6, 14 and 28 PI. This study demonstrates the feasibility of gene delivery into spinal motor neurons after injection of an HSV vector at a peripheral muscular site. This approach should prove useful in neurobiological investigations and it suggests a possible application to development of gene therapy for heritable diseases affecting motor neurons.
设计基因转移至神经系统策略的一个问题是靶向特定的神经元群体。为评估使用单纯疱疹病毒(HSV)作为基因转移至脊髓运动神经元载体的潜力,将携带大肠杆菌β-半乳糖苷酶基因的HSV-1突变体LAT-LTR(该基因在HSV LAT核心启动子(LAT)和莫洛尼鼠白血病病毒长末端重复序列(LTR)的控制下表达)单侧接种到腓肠肌中。接种后3至7天(PI)从脊髓中分离出感染性病毒。接种后第3天在脊髓同侧腹角神经元中检测到HSV抗原的免疫细胞化学标记,到接种后第6天已扩散至相邻的脊髓区域。在接种后14天或28天未检测到病毒抗原。在接种后第3、6、14和28天在腹角神经元中检测到β-半乳糖苷酶表达(由LAT-LTR启动子驱动)。组织学分析显示接种后第3天腹角有轻度病变,在接种后第6、14和28天病变进展。这项研究证明了在周围肌肉部位注射HSV载体后将基因传递到脊髓运动神经元的可行性。这种方法在神经生物学研究中应会被证明有用,并且它提示了对影响运动神经元的遗传性疾病进行基因治疗开发的一种可能应用。